UK patients with vision loss confused by ‘disjointed’ benefits registration system


Accessibility obstacles could prevent those with sight loss from receiving support and care.

A physician helps a man in sunglasses during an office visit. ©Elnur –

Sight-impaired patients in the UK report many barriers to receiving assistance. Photo credit: ©Elnur –

In the United Kingdom, registering for a Certificate of Vision Impairment (CVI) is intended to provide access to benefits. But for many citizens, the ‘disjointed’ certification process actually make it more difficult to obtain healthcare, support services and rehabilitation. Professor Shahina Pardhan, Director of the Vision and Eye Research Institute at Anglia Ruskin University (ARU), was lead author for the study, which was published in Eye.1

There are two distinct levels of CVI: sight impaired (partially sighted) and severely sight impaired (blind). A CVI enables the patient to register locally for support services, through a Referral of Vision Impairment (RVI). Receiving the certification is a laborious process – an ophthalmologist completes registration which is then approved by the patient’s primary physician, the local authority and The Royal College of Ophthalmologists Certifications Office.

But simply being certified does not trigger public assistance. Registration is voluntary, but it is another step that is required for sight-impaired patients to access services. Those benefits range from transportation to cleaning and cooking services, as well as financial aid and medical assistance.

The 17 participants in the study reported there were many barriers to care. Some were not certain how to register these services, or which they were qualified for based on their needs. Receiving certification was challenging for some patients, who found certain practitioners more likely to issue certification than others.

Even in cases where patients did receive a CVI and a referral to benefits, they faced long waitlists. One patient reported they registered for support services due to sensory impairment but did not hear back after a full year. Others said they did not know who was meant to be their point of contact for scheduling and coordinating services.

“It is clear from our research that many feel the process of registration and certification is disjointed, creating a barrier for people with sight loss,” Pardhan said.2 The researchers indicated that CVI-qualified patients deserved more clarity on a local and national level.

“More timely, efficient, and effective provision of information, advice, and signposting to relevant support services in local social care and third sector organisations, along with more informed decisions around certification and registration by eye health professionals, will benefit patients and improve their wellbeing and quality of life,” Pardhan said.


1. Pardhan, S., Driscoll, R., Ingleton, H. et al. Confusion around Certification of Vision Impairment (CVI) and registration processes—are patients falling through the cracks? Eye. April 19, 2023. Accessed May 24, 2023.
2. People with sight loss confused by ‘disjointed’ system. News release. Anglia Ruskin University, May 24, 2023.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.